SCF ENCYCLOPEDIA ENTRY
HYPERTROPHIC CARDIOMYOPATHY (HCM)
SCF SARCOMERIC HYPERCONTRACTILITY & CARDIAC SYNCHRONIZATION COLLAPSE DOSSIER
I. OFFICIAL DISEASE CLASSIFICATION
Category | Classification |
Disease Name | Hypertrophic Cardiomyopathy |
Alternative Names | HCM, Familial Hypertrophic Cardiomyopathy |
Disease Family | Inherited Cardiomyopathies |
SCF Classification | Sarcomeric Contractility & Cardiac Synchronization Failure Disorder |
Primary Clinical Domain | Cardiology, Medical Genetics, Electrophysiology, Sports Cardiology & Cardiovascular Biology |
Core Pathology | Mutations affecting cardiac sarcomere proteins resulting in myocardial hypertrophy, impaired ventricular relaxation, arrhythmias, and sudden cardiac death risk |
Principal Failure Axis | Sarcomeric mutation + hypercontractility + myocardial hypertrophy + diastolic dysfunction + electrical instability |
SCF Fault Tier | Tier IV–V Cardiac Synchronization Failure Syndrome |
Hypertrophic Cardiomyopathy belongs to SCF Clinical Domains C9 (Cardiology), C1 (Genomic Medicine), C2 (Cellular Signaling), C6 (Bioenergetics), and C13 (Systems Homeostasis).
II. CLINICAL DEFINITION
Hypertrophic Cardiomyopathy is a genetic cardiac disorder characterized by:
- Unexplained left ventricular hypertrophy
- Diastolic dysfunction
- Myocardial fibrosis
- Arrhythmias
- Sudden cardiac death risk
- Variable heart failure symptoms
Primary affected systems:
- Cardiac sarcomeres
- Ventricular myocardium
- Cardiac conduction networks
- Coronary microvasculature
- Autonomic regulation systems
Associated conditions:
- Cardiomyopathy
- Sudden cardiac death
III. MAJOR CLASSIFICATIONS
A. Obstructive Hypertrophic Cardiomyopathy (HOCM)
Feature | Description |
LVOT Obstruction | Present |
Frequency | Most common subtype |
Symptoms | Often exertional |
Associated condition:
- Left ventricular outflow tract obstruction
B. Non-Obstructive Hypertrophic Cardiomyopathy
Feature | Description |
LVOT Obstruction | Absent |
Hypertrophy | Present |
Disease Burden | Variable |
C. Apical Hypertrophic Cardiomyopathy
Feature | Description |
Hypertrophy Location | Cardiac apex |
Prevalence | Less common |
Prognosis | Often more favorable |
D. End-Stage (“Burned-Out”) HCM
Feature | Description |
Systolic Dysfunction | Present |
Fibrosis | Extensive |
Heart Failure Risk | High |
Associated condition:
- Heart failure
IV. CORE SCF ETIOPATHOGENIC THESIS
Within the Synergistic Compatibility Framework (SCF), Hypertrophic Cardiomyopathy represents a systems-level collapse of:
- Cardiac contractile harmonics
- Sarcomeric force regulation
- Myocardial energy optimization
- Ventricular filling synchronization
- Electromechanical communication networks
SCF interprets HCM as a decentralized cardiac intelligence disorder in which excessive contractile signaling progressively disrupts myocardial architecture, energy balance, and electrical stability.
V. SARCOMERIC FOUNDATION
Normal Sarcomere Function
The cardiac sarcomere coordinates:
- Force generation
- Cardiac contraction
- Mechanical efficiency
- Ventricular ejection
- Electromechanical coupling
Core Pathophysiologic Mechanisms
Mechanism | Consequence |
Sarcomeric mutation | Hypercontractility |
Increased ATP demand | Energetic stress |
Myocyte hypertrophy | Ventricular thickening |
Fibrosis formation | Electrical instability |
Diastolic dysfunction | Impaired filling |
Microvascular dysfunction | Ischemia |
VI. MAJOR GENETIC CAUSES
Principal Genes
Gene | Protein |
MYBPC3 | Myosin-binding protein C |
MYH7 | β-Myosin heavy chain |
TNNT2 | Cardiac troponin T |
TNNI3 | Cardiac troponin I |
TPM1 | α-Tropomyosin |
ACTC1 | Cardiac actin |
Genetic Characteristics
Feature | Description |
Inheritance | Autosomal dominant |
Penetrance | Variable |
Expressivity | Variable |
Family Screening | Recommended |
Associated condition:
- Autosomal dominant disorder
VII. SCF FAULT ARCHITECTURE
SCF Fault Node | Biological Consequence |
Sarcomeric dysfunction | Hypercontractility |
ATP overconsumption | Energetic inefficiency |
Myocyte hypertrophy | Ventricular thickening |
Fibrosis accumulation | Signal disruption |
Diastolic impairment | Reduced filling |
Electrical instability | Arrhythmias |
Coronary microvascular dysfunction | Ischemia |
Electromechanical uncoupling | Functional decline |
Cardiac synchronization failure | Progressive cardiomyopathy |
VIII. MULTI-OMICS PATHOGENESIS
A. Genomics
Affected pathways:
- Sarcomere assembly
- Contractile regulation
- Mechanotransduction
- Cardiac development
B. Transcriptomics
Dysregulated pathways:
- Hypertrophic signaling
- Fibrosis pathways
- Calcium handling
- Stress adaptation
C. Proteomics
Observed abnormalities:
- Sarcomeric proteins
- Calcium-regulatory proteins
- Fibrotic mediators
- Contractility regulators
D. Metabolomics
Key dysfunction:
- ATP depletion
- Mitochondrial stress
- Oxidative stress
- Energetic inefficiency
E. Cardiomics (SCF)
Observed abnormalities:
- Contractile overactivation
- Synchronization instability
- Ventricular communication impairment
- Mechanical inefficiency
IX. SCF PATHOGENESIS FLOW
Stage 1 — Sarcomeric Mutation
Contractile regulation becomes abnormal.
Stage 2 — Hypercontractility
Cardiac force generation becomes excessive.
Stage 3 — Myocardial Hypertrophy
Myocytes enlarge and remodel.
Stage 4 — Fibrosis & Electrical Instability
Conduction abnormalities emerge.
Stage 5 — Diastolic Dysfunction
Ventricular filling becomes impaired.
Stage 6 — Advanced Cardiac Disease
Heart failure, arrhythmias, or sudden death risk develops.
X. SYSTEMIC CONSEQUENCES
Consequence | Mechanism |
Dyspnea | Diastolic dysfunction |
Chest pain | Microvascular ischemia |
Syncope | Arrhythmias or obstruction |
Atrial fibrillation | Atrial remodeling |
Ventricular tachyarrhythmias | Electrical instability |
Sudden cardiac death | Malignant arrhythmias |
Associated conditions:
- Atrial fibrillation
- Ventricular tachycardia
- Syncope
XI. RHENOVA INTERPRETATION
Project RHENOVA interprets HCM as a cardiac force-amplification destabilization syndrome.
RHENOVA Dynamics
- Contractile amplification loops
- Energy-consumption escalation
- Fibrosis propagation cascades
- Electromechanical uncoupling
- Cardiac synchronization collapse
RHENOVA Biomarkers
Biomarker | Significance |
Echocardiographic wall thickness | Disease severity |
Cardiac MRI fibrosis burden | Prognosis |
Troponin | Myocardial stress |
NT-proBNP | Heart failure burden |
Genetic testing | Molecular diagnosis |
XII. DBI INTERPRETATION
The SCF Decentralized Biological Intelligence framework interprets the heart as a distributed biomechanical intelligence network coordinating:
- Force generation
- Electrical conduction
- Perfusion regulation
- Rhythm maintenance
- Systemic circulation
DBI Failure Features
- Contractile over-signaling
- Energetic inefficiency
- Electrical communication disruption
- Mechanical synchronization loss
This transforms a highly coordinated cardiac network into an increasingly unstable electromechanical system.
XIII. CLINICAL MANIFESTATIONS
Cardiovascular Manifestations
- Exertional dyspnea
- Chest pain
- Palpitations
- Syncope
- Exercise intolerance
Associated condition:
- Palpitations
Rhythm Manifestations
- Atrial fibrillation
- Ventricular tachycardia
- Sudden cardiac arrest
Associated condition:
- Cardiac arrest
Structural Manifestations
- Asymmetric septal hypertrophy
- Left ventricular hypertrophy
- Mitral valve abnormalities
Associated condition:
- Left ventricular hypertrophy
XIV. DIAGNOSTICS
Modality | Utility |
Echocardiography | Primary diagnostic tool |
Cardiac MRI | Fibrosis and anatomy assessment |
ECG | Electrical evaluation |
Genetic testing | Molecular diagnosis |
Exercise testing | Risk stratification |
Diagnostic Hallmarks
Sarcomeric principle:
Mechanical relationship:
Clinical consequence:
XV. SCF SYSTEMIC AXIS INVOLVEMENT
Axis | Dysfunction |
Contractility Axis | Hyperactivation |
Electrical Axis | Arrhythmogenesis |
Bioenergetic Axis | ATP stress |
Structural Axis | Hypertrophy and fibrosis |
Perfusion Axis | Microvascular dysfunction |
Synchronization Axis | Electromechanical instability |
XVI. STANDARD OF CARE
Pharmacologic Therapy
Examples:
- Metoprolol
- Verapamil
- Mavacamten
Procedural Therapy
Examples:
- Septal myectomy
- Alcohol septal ablation
Sudden Death Prevention
Example:
- Implantable cardioverter-defibrillator
XVII. SCF-PCR THERAPEUTIC ARCHITECTURE
A. Preventative (PCR-P)
Goals:
- Prevent arrhythmias
- Reduce fibrosis progression
- Preserve ventricular function
B. Curative (PCR-C)
Goals:
- Correct sarcomeric dysfunction
- Normalize contractile regulation
- Restore genetic homeostasis
C. Restorative (PCR-R)
Goals:
- Improve cardiac efficiency
- Restore electromechanical stability
- Reduce energetic stress
- Rebuild myocardial synchronization harmonics
XVIII. ETHNOBIOPROSPECTING TARGETS
Note: These represent exploratory cardioprotective research domains and are not substitutes for evidence-based cardiac management.
Traditional Chinese Medicine
- Salvia miltiorrhiza
- Astragalus membranaceus
Ayurveda
- Terminalia arjuna
- Withania somnifera
Vietnamese Thuốc Nam
- Nelumbo nucifera
XIX. SCF API DISCOVERY TARGETS
High-Priority Molecular Targets
- Sarcomere-modulating therapeutics
- Cardiac myosin regulators
- Fibrosis-reduction technologies
- Mitochondrial optimization platforms
- Electrophysiologic stabilization therapies
- Precision gene-editing approaches for HCM
- Cardiac synchronization restoration systems
XX. SCF LAYMAN’S SUMMARY
Hypertrophic Cardiomyopathy is a genetic heart disease in which the heart muscle becomes abnormally thick, most often due to mutations affecting the proteins responsible for cardiac contraction. The thickened heart can have difficulty relaxing, filling properly, and maintaining normal electrical rhythms. Some individuals remain symptom-free, while others develop shortness of breath, chest pain, fainting episodes, arrhythmias, heart failure, or sudden cardiac death. SCF interprets HCM as a disorder of excessive cardiac contractile signaling that gradually disrupts the heart’s mechanical, electrical, and energetic synchronization systems.
XXI. STRATEGIC RESEARCH PRIORITIES
- Sarcomere-modulating therapies
- Cardiac myosin inhibition platforms
- Anti-fibrotic cardiac therapeutics
- AI-driven arrhythmia and sudden-death forecasting systems
- Precision HTT? (correction: HCM-associated sarcomeric gene) editing technologies
- Mitochondrial optimization strategies
- Cardiac synchronization restoration platforms
MASTER REGISTRY INDEX
SCF-HCM-0001 — Hypertrophic Cardiomyopathy Master Registry
SCF-HCM-SARCOMERE-0002 — Sarcomeric Hypercontractility Layer
SCF-HCM-FIBROSIS-0003 — Myocardial Remodeling Layer
SCF-HCM-RHENOVA-0004 — Cardiac Force-Amplification Destabilization Layer
SCF-HCM-DBI-0005 — Electromechanical Communication Failure Layer
SCF-HCM-PCR-0006 — Preventative–Curative–Restorative Layer